Innovation
Keeping the lights on for CNS
For the healthcare providers, patients, caregivers, advocates, and scientists, SK Life Science, Inc. (SKLSI) is here listening to your needs, developing new molecules, enhancing advocacy efforts, and providing solutions that change what’s possible in CNS treatment.
Our Medicines
SK Life Science is committed to accelerating the development of next generation treatments for CNS disorders. SK Biopharmaceuticals and SK Life Science independently developed XCOPRI® from inception through to FDA approval.
The two companies also discovered and licensed-out the FDA and EMA-approved treatment for sleep disorders after completing phase 1 clinical trials.
For any medical information inquiries on our medicines, please visit medicalinfo.sklifescienceinc.com
Our Global Pipeline
SK Life Science and its parent company SK Biopharmaceuticals have 8 compounds under development globally.
Invigorating next-generation discovery
We are a group of scientists, inventors, and explorers working to unlock the complex mysteries of the brain
Leveraging technologies to include:
Target-based drug discovery techniques
High throughput organic screening (HTOS)/high content screening (HCS)
Computer-aided drug design (CADD)
Combinatorial chemistry
Key R&D sectors
We deploy our technologies in the areas of biology/discovery, medicinal chemistry, and pharmacology. The goal of research in these areas is to bring meaningful products to market.
Select a sector for details
Grant Requests
Medical Education Grant Request
Please complete and return the Medical Education Grant Request form and the outlined documents to request a Medical Education Grant. Grant requestors will be notified within 30 days of submission. The documents listed in the form must be submitted to Grants@SKLSI.com, along with a completed Medical Education Grant Request form.
Medical Education Grant Request FormInvestigator Initiated Study Proposal Procedure
All requested information must be submitted to Grants@SKLSI.com. Decisions are made based on medical and scientific merit as well as available budget.
Following the submission:
- SK Life Science will acknowledge receipt of all Investigator Initiated Study proposals by email.
- The Investigator Initiated Study (IIS) Committee will review the form to determine SK Life Science initial interest in the proposal.
- The submitter will need to provide certain documents, including a full protocol, which will be reviewed by the IIS Committee if the Committee has interest in the proposal.
- A formal notification of the outcome of the review will be sent by email.
Expanded Access & Compassionate Use
Click here to learn information about SK Life Science’s Expanded Access and Compassionate Use policy.
Expanded Access Requests for Investigational ProductsTransparency
Vermont State Regulations
Long form disclosure for XCOPRI® (cenobamate tablets) CV
Short form disclosure for XCOPRI® (cenobamate tablets) CV
Colorado State Regulations
XCOPRI® (cenobamate tablets) CV disclosure form